MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy

Background/Aim: Here, we investigated whether bortezomib as a maintenance therapy affected outcomes in transplant-ineligible patients with multiple myeloma (MM). Patients and Methods: Following induction therapy with bortezomib, maintenance therapy with bortezomib (1.3 mg/m2) and dexamethasone (20 mg) was administered once or twice every 4 weeks until disease progression. The endpoints of this study were time to next treatment and overall survival. Results: Seventy-six newly diagnosed, transplant-ineligible patients were treated with a bortezomib-based regimen; 28 discontinued induction therapy, 27 did not receive maintenance therapy after induction therapy (the non-maintenance group), and 21 did (the maintenance group). In the three groups, the median times to the next required treatment were 3, 14, and 37 months, respectively. The 3-year overall survival rates were 55%, 69%, and 85%, respectively. There were no significant differences in patient characteristics between the non-maintenance and maintenance groups, except for poorer estimated glomerular filtration rates in the maintenance group. Conclusion: Bortezomib maintenance therapy may be a useful option for transplant-ineligible patients with MM.

show abstract

Polymeric Nanoparticles and Their Novel Modifications for Targeted Delivery of Bortezomib

Allahyari

Valizadeh

Zakeri–Milani

2020

Pharm Sci

View full text Add to dashboard Cite

Bortezomib (BTZ) as a specific proteasome inhibitor is used to inhibit proliferation and migration of tumor cell in variety of cancers. Targeted delivery of this drug not only would minimize its unwanted side effects but also might improve its efficacy. This purpose could be gotten through different pathways but using efficient carriers may be the best one without using any additional ingredients/ materials. Some polymer based nanoparticles with specific functional groups have the ability to interact with boronic acid moiety in BTZ. This reaction might play an important role not only in cancer targeting therapy but also in loading and release properties of this drug. Novel modification such as making multifunctional or pH-sensitive nanocarriers, may also improve anticancer effect of BTZ. This review might have remarkable effect on researchers’ consideration about other possible interactions between BTZ and polymeric nanocarriers that might have great effect on its remedy pathway. It has the ability to brought bright ideas to their minds for novel amendments about other drugs and delivery systems.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy

Cited by 4 publications

References 32 publications

The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era

The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era

Maintenance Therapy With Bortezomib and Dexamethasone for Transplant-ineligible Patients With Multiple Myeloma

Polymeric Nanoparticles and Their Novel Modifications for Targeted Delivery of Bortezomib

Contact Info

Product

Resources

About